Hypertension in peritoneal dialysis patients: Epidemiology, pathogenesis, and treatment

Journal of the American Society of Hypertension

Volumn 5, Issue 3, 2011, Pages 128-136

  Ortega, Luis M ^a   Materson, Barry J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

end stage kidney disease; left ventricular hypertrophy; Peritoneal dialysis; peritoneal dialysis solutions; residual renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLIC GMP; DIALYSIS FLUID; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FUROSEMIDE; GLUCOSE; GLUCOSE DERIVATIVE; ICODEXTRIN; LOOP DIURETIC AGENT; RAMIPRIL; SODIUM; SODIUM CHLORIDE; VALSARTAN;

ACTION POTENTIAL; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ANURIA; BLOOD PRESSURE REGULATION; BODY FAT; CARDIOVASCULAR DISEASE; COLLOID; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEHYDRATION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DRUG SAFETY; DRY WEIGHT; EXTRACELLULAR SPACE; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERVOLEMIA; HYPOALBUMINEMIA; HYPOTENSION; INFERIOR CAVA VEIN; KIDNEY FAILURE; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; MEMBRANE TRANSPORT; MORTALITY; OSMOSIS; OTOTOXICITY; PATHOGENESIS; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SODIUM EXCRETION; SODIUM RESTRICTION; SURVIVAL; SYSTOLIC BLOOD PRESSURE; THIRST; TREATMENT DURATION; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; VASCULAR RESISTANCE; WATER TRANSPORT; WEIGHT GAIN;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY COMPOSITION; ELECTRIC IMPEDANCE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PERITONEUM; PREVALENCE; SODIUM CHLORIDE, DIETARY; ULTRAFILTRATION; WATER-ELECTROLYTE IMBALANCE;

EID: 79955587650     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2011.02.004     Document Type: Review

References (49)

1. Negoi D, Nolph KD. History of peritoneal dialysis. In: Khanna R, Krediet R, editors. Nolph and Gokal's Textbook of Peritoneal Dialysis. 3rd ed. New York: Springer; 2009:3.
2. United States Renal Data System. 2010 Annual Data Report, volume 2. 2010 Atlas of End-Stage Renal Disease in the United States. p 26, Figure 5.
3. Mehrotra R, Boeschoten EW. Currents status of peritoneal dialysis. In: Khanna R, Krediet R, editors. Nolph and Gokal's Textbook of Peritoneal Dialysis. 3rd ed. New York: Springer; 2009:21.
4. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009;53:500-7.
5. Günal AI, Duman S, Özkahya M, Töz H, Asçi G, Akçiçek F, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001;37:588-93. (Pubitemid 32195299)
6. Rohrscheib MR, Myers OB, Servilla KS, Adams CD, Miskulin D, Bedrick EJ, et al. Age-related blood pressure patterns and blood pressure variability among hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1407-14.
7. Bargman JM, Thorpe KE. Churchill DN for the CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-62. (Pubitemid 32880353)
8. Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 2009;24:2620-2.
9. Lang SM, Bergner A, Töpfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 2001;21:52-8.
10. Liao C-T, Chen Y-M, Shiao C-C, Hu F-C, Huang J-W, Kao T-W, et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009;24:2909-14.
11. Cocchi R, Esposti ED, Fabbri A, Lucatello A, Sturani A, Quarello F, et al. Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study. Nephrol Dial Transplant 1999;14:1536-40. (Pubitemid 29241751)
12. Cheigh JS, Kim H. Hypertension in a continuous ambulatory peritoneal dialysis patient: what do we know and what can we do about it? Perit Dial Int 1999;19(suppl 2):S138-43.
13. Udayaraj UP, Steenkamp R, Caskey FJ, Rogers C, Nitsch D, Ansell D, et al. Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis 2009;53:70-8.
14. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001;16:2207-13. (Pubitemid 33062145)
15. Jager KJ, Merkus MP, Dekker FW, Boeschotten EW, Tijssen JGP, Stevens P, et al. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of the Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int 1999;55:1476-85. (Pubitemid 29157147)
16. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2005;20:1693-701. (Pubitemid 41418596)
17. Malliara M, Passadakis P, Panagoutsos S, Theodoridis M, Thodis E, Bargman J, et al. Hypotension in patients on chronic peritoneal dialysis: etiology, management, and outcome. Adv Perit Dial 2002;18:49-54.
18. Konings CJAM, Kooman JP, Schonck M, Dammers R, Cheriex E, Palmans Meulemans AP, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002;22:477-87. (Pubitemid 35012264)
19. Heaf J. Pathogenic effects of a high peritoneal transport rate. Semin Dial 2000;13:188-93.
20. Preston R, Singer I, Epstein M. Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med 1996;156:602-11. (Pubitemid 126510076)
21. Slingeneyer A, Canaud B, Mion C. Permanent loss of ultrafiltration capacity of the peritoneum in long-term peritoneal dialysis: an epidemiological study. Nephron 1983;33:133-8. (Pubitemid 13190901)
22. Devolder I, Verleysen A, Vijt D, Vanholder R, Van Viesen W. Body composition, hydration, and related parameters in hemodialysis versus peritoneal dialysis patients. Perit Dial Int 2010;30:208-14.
23. Aanen M, Venturoli D, Davies SJ. A detailed analysis of sodium removal by peritoneal dialysis: comparison with predictions from the three-pore model of membrane function. Nephrol Dial Transplant 2005;20:1192-200. (Pubitemid 40862110)
24. Tan BK, Chan C, Davies SJ. Achieving euvolemia in peritoneal dialysis patients: a surprisingly difficult proposition. Semin Dial 2010;23:456-61.
25. Zhu F, Hoenich NA, Kaysen G, Ronco C, Schneditz D, Murphy L, et al. Measurement of intraperitoneal volume by segmental bioimpedance analysis during peritoneal dialysis. Am J Kidney Dis 2003;42:167-72. (Pubitemid 36807666)
26. Cigarran S, Barril G, Cirugeda A, Bernis C, Aguilera A, Sanx P, et al. Hypoalbuminemia is also a marker of fluid excess determined by bioelectrical impedance parameters in dialysis patients. Ther Apher Dial 2007;11:114-20. (Pubitemid 46449862)
27. Rodriguez-Carmona A, Pérez-Fontán M, García-Naveiro R, Villaverde P, Peteiro J. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004;44:132-45. (Pubitemid 38880935)
28. Rodriguez-Carmona A, Pérez-Fontán M. Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int 2002;22:705-13. (Pubitemid 36131501)
29. Silaruks S, Sirivongs D, Chunlertrith D. Left ventricular hypertrophy and clinical outcome in CAPD patients. Perit Dial Int 2000;20:461-6.
30. Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999;14:2178-83. (Pubitemid 29403408)
31. Guida B, Piccoli A, Trio R, Laccetti R, Nastasi A, Paglione A, et al. Dietary phosphate restriction in dialysis patients: a new approach for the treatment of hyperphosphataemia. Nutr Metab Cardiovasc Dis 2010; July 5 (Epub ahead of print).
32. Kuhlmann MK. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 2010; 29:137-44.
33. Levin NW, Kotanko P, Eckardt K-U, Kasiske BL, Chazot C, Cheung AK, et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2010;77:273-84.
34. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 2000;15:862-6. (Pubitemid 30312008)
35. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003;14:2338-44. (Pubitemid 37052381)
36. Poole CYL, Welten AGA, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005;25(S3):S64-8.
37. Konings CJAM, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18:797-803. (Pubitemid 36432264)
38. Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant 2002;17:1661-6. (Pubitemid 35012171)
39. Fine A, Fontaine B, Ma M. Commonly prescribed salt intake in continuous ambulatory peritoneal dialysis is too restrictive: results of a double-blind crossover study. J Am Soc Nephrol 1997;8:1311-4. (Pubitemid 27493637)
40. Griffith TF, Chua BSY, Allen AS, Klassen PS, Reddan DN, Szczech LA. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003;42: 1260-9. (Pubitemid 37486771)
41. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002;61:2157-64. (Pubitemid 34539333)
42. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002;40:1023-9. (Pubitemid 35265483)
43. Medcalf JF, Harris KPG, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001;59:1128-33. (Pubitemid 32206877)
44. Grzegorzewska A, Krzymanski M, Uchman G, Antoniewicz K, Baczyk K. High intraperitoneal furosemide doses in long-dwell exchange. Adv Perit Dial 1988;4:51-6.
45. van Olden RW, Guchelaar H-J, Struijk DG, Krediet RT, Arisz L. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 2003;23:339-47.
46. Buckalew VM Jr, Berg RL, Wang S-R, Porush JG, Rauch S, Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the Modification of Diet in Renal Disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996;28:811-21.
47. Li PK-T, Chow K-M, Wong TY-H, Leung C-B, Szeto C-C. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized controlled study. Ann Intern Med 2003;139:105-12.
48. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43:1056-64. (Pubitemid 38691501)
49. Kolesnyk I, Noordzij M, Dekker FW, Boeschoeten EW, Krediet RT. Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Perit Dial Int 2011;31:53-9.